摘要
Objective: To explore the therapeutic effect of elemene combined with S-1 / oxaliplatin (SOX) in the treatment of advanced metastatic gastric cancer, and to analyze and evaluate the safety of the chemotherapy, so as to provide new ideas for clinical treatment. Methods: 71 patients with advanced metastatic gastric cancer from April 2015 to April 2018 were randomly divided into two groups: the control group treated with SOX alone and the observation group treated with elemene combined SOX. The short-term and long-term therapeutic effects of the two groups were compared by the RECIST1.1 score and survival curve, and the differences of tumor markers, serological indicators and adverse reactions between the two groups were compared. Results: the objective remission rate (ORR) and clinical benefit rate (CBR) of the observation group were significantly higher than those of the control group (χ2=5.161, P=0.031;χ2=5.124, P=0.037);after treatment, the serum CEA, CA-199, IGF-1, MMP-9, IL-2 and IFN-γ levels of the observation group were significantly improved compared with those of the control group (P<0.05);compared with the two groups, the incidence of leucopenia, anemia, asthenia, nausea and vomiting in the observation group were significantly lower than that in the control group (P<0.05);the median tumor progression time (7.1 months, 95%CI=4.037-10.248) and median total survival time (8.8 months, 95%CI=6.634-10.907) in the observation group were significantly higher than that in the control group (4.9 months, 95%CI=2.324-6.839) and median total survival time (6.5 months, 95%CI=5.007-7.638), and the difference was statistically significant (P=0.001, P=0.026). Conclusion: elemene combined with SOX has a high short-term and long-term efficacy in patients with advanced metastatic gastric cancer, and its side effects are less, and its safety is higher, which has a certain clinical significance.
基金
Wu Jieping medical foundation project (320.3750.18075)
